연구개발
전문가와 협업을 통해 다양한 R&D에 투자 함으로써 언제나 더 나은 미래를 모색 합니다.
전문가와 협업을 통해 다양한 R&D에 투자 함으로써 언제나 더 나은 미래를 모색 합니다.
2018
스토바코R정 0.5,1(Smoking Cessation agent)
New Salt
2019
UI026(Antitussive)
New dosage form
UI014(Lipid modifying agent)
New dosage form
UI035(Nootropics & Neurotonics)
New dosage form
UI044, UI054 (Lipid modifying agent)
New dosage form
2020
UI018(Lipid modifying agent)
New Combination
UI020(Antidiabetics)
New dosage form
UI017(Platelet aggregation inh.)
New dosage form
UI009, UI010(COPD)
DPI
2021
UI055(Rheumatoid Arthritis)
New Salt
UI036(Platelet aggregation inh.)
New dosage form
UI015(NSAIDs)
New dosage form
UI028(Functional GI disorder)
New Combination
UI022, UI023(Platelet aggregation inh.)
New Combination
UI050(Antidiabetics)
Co-crystal
2022
UI032(NSAIDs)
New Combination
UI046(Nootropics & Neurotonics)
Controlled Release
UI037, UI051(Antidiabetics)
New Salt
UI038, UI039, UI040(Antidiabetics)
New Combination
UI047(Antidiabetics)
New Combination
UI030, UI031(COPD)
New Device, Isomer
2023
UI053 (Chronic Pain)
New Combination
UI049(NERD)
New Combination
2024
UI056(Rheumatoid Arthritis)
Controlled Release
UI057(Overactive Bladder)
Controlled Release
2025
UI033, UI034(Asthma)
Isomer
UI048(Antidiabetics, Pain)
New Combination
UI027(Antitussive)
New Combination